Peptide Research: Retatrutide – Studies, Research Use, and Scientific Background

What is Retatrutide?

Retatrutide is a novel investigational peptide and triple agonist targeting the GLP-1, GIP, and glucagon receptors. Designed for advanced metabolic research, Retatrutide has gained attention for its ability to engage multiple pathways involved in glucose regulation, weight management, and appetite control in laboratory models.
For laboratory research use only. Not for human or veterinary use.

Key Scientific Studies

  • Triple Agonist Mechanism: A 2022 study published in Nature Medicine reported that Retatrutide, as a triple hormone receptor agonist, led to significant reductions in body weight and improvements in metabolic markers in preclinical and early clinical research subjects.
    Jastreboff et al., 2022
  • Laboratory Findings: Additional laboratory studies highlight Retatrutide’s impact on glucose tolerance, lipid metabolism, and appetite signaling pathways in animal models and in vitro research.
    Killion et al., 2023

Laboratory Research Applications

  • Study of metabolic and energy regulation pathways
  • Investigation of GLP-1, GIP, and glucagon receptor interactions
  • Preclinical models of obesity, diabetes, and metabolic disorders
  • Research on appetite regulation and energy expenditure

Mechanism of Action (in Research Context)

Retatrutide acts as a triple agonist, simultaneously activating the GLP-1, GIP, and glucagon receptors. In laboratory studies, this multi-receptor engagement has been shown to enhance glucose homeostasis, increase energy expenditure, and support significant reductions in body weight in animal models. Its structure enables comprehensive metabolic pathway research in advanced preclinical settings.

Reference Dosing Schedules from Published Studies

For Laboratory Reference Only – Not Medical Advice or Guidance

Recent published studies and clinical trials have investigated the following dosing schedules for Retatrutide in research settings:

  • Initial Dose: 2 mg once weekly for the first two weeks
  • Titration: Gradual increase in dose over subsequent weeks, as outlined in study protocols
  • Maintenance Dose: Doses up to 8 mg once weekly have been evaluated in clinical research
References:
Jastreboff AM, et al. Nature Medicine (2022). Read Study
Killion EA, et al. Journal of Endocrinology (2023). Read Study
ClinicalTrials.gov Identifier: NCT04881760
Important: Endura Lyfe products are for laboratory research use only and are not for human or veterinary use. All information above is cited for scientific reference from published research and is not to be interpreted as medical advice or guidance for human use.
Shopping Cart